These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19053752)

  • 1. Cytochrome P450 2C9 type II binding studies on quinoline-4-carboxamide analogues.
    Peng CC; Cape JL; Rushmore T; Crouch GJ; Jones JP
    J Med Chem; 2008 Dec; 51(24):8000-11. PubMed ID: 19053752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theoretical study of the ligand-CYP2B4 complexes: effect of structure on binding free energies and heme spin state.
    Harris DL; Park JY; Gruenke L; Waskell L
    Proteins; 2004 Jun; 55(4):895-914. PubMed ID: 15146488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploration of the binding of proton pump inhibitors to human P450 2C9 based on docking and molecular dynamics simulation.
    Shi R; Li J; Cao X; Zhu X; Lu X
    J Mol Model; 2011 Aug; 17(8):1941-51. PubMed ID: 21120554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution.
    Wester MR; Yano JK; Schoch GA; Yang C; Griffin KJ; Stout CD; Johnson EF
    J Biol Chem; 2004 Aug; 279(34):35630-7. PubMed ID: 15181000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visible spectra of type II cytochrome P450-drug complexes: evidence that "incomplete" heme coordination is common.
    Locuson CW; Hutzler JM; Tracy TS
    Drug Metab Dispos; 2007 Apr; 35(4):614-22. PubMed ID: 17251307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of the affinity and metabolism of type I and type II binding quinoline carboxamide analogues by cytochrome P450 3A4.
    Dahal UP; Joswig-Jones C; Jones JP
    J Med Chem; 2012 Jan; 55(1):280-90. PubMed ID: 22087535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.
    Zhou SF; Zhou ZW; Yang LP; Cai JP
    Curr Med Chem; 2009; 16(27):3480-675. PubMed ID: 19515014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effector-mediated alteration of substrate orientation in cytochrome P450 2C9.
    Hummel MA; Gannett PM; Aguilar JS; Tracy TS
    Biochemistry; 2004 Jun; 43(22):7207-14. PubMed ID: 15170358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intramolecular heme ligation of the cytochrome P450 2C9 R108H mutant demonstrates pronounced conformational flexibility of the B-C loop region: implications for substrate binding.
    Roberts AG; Cheesman MJ; Primak A; Bowman MK; Atkins WM; Rettie AE
    Biochemistry; 2010 Oct; 49(40):8700-8. PubMed ID: 20815369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid.
    Schoch GA; Yano JK; Sansen S; Dansette PM; Stout CD; Johnson EF
    J Biol Chem; 2008 Jun; 283(25):17227-37. PubMed ID: 18413310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part II.
    Mo SL; Zhou ZW; Yang LP; Wei MQ; Zhou SF
    Curr Drug Metab; 2009 Dec; 10(10):1127-50. PubMed ID: 20167000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure of mammalian cytochrome P450 2B4 complexed with 4-(4-chlorophenyl)imidazole at 1.9-A resolution: insight into the range of P450 conformations and the coordination of redox partner binding.
    Scott EE; White MA; He YA; Johnson EF; Stout CD; Halpert JR
    J Biol Chem; 2004 Jun; 279(26):27294-301. PubMed ID: 15100217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Site of metabolism prediction on cytochrome P450 2C9: a knowledge-based docking approach.
    Tarcsay A; Kiss R; Keseru GM
    J Comput Aided Mol Des; 2010 May; 24(5):399-408. PubMed ID: 20361237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flexibility of human cytochrome P450 enzymes: molecular dynamics and spectroscopy reveal important function-related variations.
    Hendrychová T; Anzenbacherová E; Hudeček J; Skopalík J; Lange R; Hildebrandt P; Otyepka M; Anzenbacher P
    Biochim Biophys Acta; 2011 Jan; 1814(1):58-68. PubMed ID: 20656072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I.
    Mo SL; Zhou ZW; Yang LP; Wei MQ; Zhou SF
    Curr Drug Metab; 2009 Dec; 10(10):1075-126. PubMed ID: 20167001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative binding models for CYP2C9 based on benzbromarone analogues.
    Locuson CW; Rock DA; Jones JP
    Biochemistry; 2004 Jun; 43(22):6948-58. PubMed ID: 15170332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation, characterization, and substrate metabolism of gold-immobilized cytochrome P450 2C9.
    Gannett PM; Kabulski J; Perez FA; Liu Z; Lederman D; Locuson CW; Ayscue RR; Thomsen NM; Tracy TS
    J Am Chem Soc; 2006 Jul; 128(26):8374-5. PubMed ID: 16802783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of arginine 97 and lysine 72 as determinants of substrate specificity in cytochrome P450 2C9 (CYP2C9).
    Davies C; Witham K; Scott JR; Pearson A; DeVoss JJ; Graham SE; Gillam EM
    Drug Metab Dispos; 2004 Apr; 32(4):431-6. PubMed ID: 15039296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional analysis of phenylalanine residues in the active site of cytochrome P450 2C9.
    Mosher CM; Hummel MA; Tracy TS; Rettie AE
    Biochemistry; 2008 Nov; 47(45):11725-34. PubMed ID: 18922023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformational changes near the cytochrome P450 active site upon binding of two different ligands.
    Myasoedova KN; Timofeev KN
    Biochemistry (Mosc); 2010 Jul; 75(7):899-904. PubMed ID: 20673214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.